Abstract
We studied loracarbef (LCBF), a new oral carbacephem antibiotic, for its clinical efficacy in the treatment of skin and soft-tissue infections.
A total of 53 patients diagnoses consisting of infected atheroma, felon, phlegmon, subcutaneous abscess, wound infection, furunculosis, lymphadentitis, lymphangitis, paronychia and mastitis, were treated.
The clinical effect in 53 cases was assessed by the doctor in charge as excellent in 9 cases, good in 35, fair in 6, and poor in 3.The efficacy rate was 83.0%.
The clinical effect as assessed according to the standard criteria was excellent in 22, good in 25, fair in 3 and poor in 3, the efficacy rate being 88.7%.
In the bacterial evaluation, the eradication rate in 20 cases of monomicrobial infection was 100%, and in 18 cases of polymicrobial infection, 83.3%.
No adverse reactions were observed in 53 cases.No abnormal laboratory findings were noted in any of the cases evaluated.
MICs of LCBF were determined against 59 clinically isolated strains of 21 species.Those for 52 (88.1%) of the 59 strains were 6.25μg/ml or less.
